Zomedica (ZOM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive compensation and say-on-pay
Compensation for Tony Blair (COO) and Karen DeHaan-Fullerton (General Counsel & Corporate Secretary) for 2023 was updated to include salary, bonus, option awards, and other compensation.
Tony Blair's total compensation for 2023 was $333,011, and for 2024 is $367,782.
Karen DeHaan-Fullerton's total compensation for 2023 was $295,089, and for 2024 is $367,542.
Option awards are valued at grant date fair value per FASB ASC Topic 718; actual realized value depends on share price at exercise.
Other compensation includes vacation payout and accruals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zomedica
- Profitability targeted for 2027, with strong R&D and product innovation fueling growth.ZOM
Status update27 Feb 2026 - Innovative veterinary solutions and recurring revenue drive high growth and margin expansion.ZOMSmall-Cap Growth Virtual Investor Conference1 Feb 2026
- Q2 revenue up 2% to $6.1M, but net loss surged on $16M impairment; margin reached 71%.ZOMQ2 20241 Feb 2026
- AI-driven platforms and recurring revenue position the company for profitability by 2027.ZOMStatus update1 Feb 2026
- Q3 revenue up 10% to $7M, 72% margin, net loss $6.7M, global expansion ongoing.ZOMQ3 202415 Jan 2026
- Record $27.3M revenue, 70% margin, and strong liquidity set stage for 2025 growth.ZOMQ4 202419 Dec 2025
- Virtual meeting to elect directors, ratify auditor, and hold say-on-pay vote, with strong governance.ZOMProxy Filing2 Dec 2025
- Virtual annual meeting set for June 10; all shareholders urged to vote by June 8.ZOMProxy Filing2 Dec 2025
- Virtual annual meeting to vote on directors, auditor, and executive pay, with online access promoted.ZOMProxy Filing2 Dec 2025